Neoadjuvant Chemoimmunotherapy for NSCLC

Mark Sorin,Connor Prosty,Louis Ghaleb,Kathy Nie,Khaled Katergi,Muhammad H. Shahzad,Laurie-Rose Dubé,Aline Atallah,Anikka Swaby,Matthew Dankner,Trafford Crump,Logan A. Walsh,Pierre O. Fiset,Boris Sepesi,Patrick M. Forde,Tina Cascone,Mariano Provencio,Jonathan D. Spicer
DOI: https://doi.org/10.1001/jamaoncol.2024.0057
IF: 33.006
2024-03-21
JAMA Oncology
Abstract:Importance To date, no meta-analyses have comprehensively assessed the association of neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer (NSCLC) in randomized and nonrandomized settings. In addition, there exists controversy concerning the efficacy of neoadjuvant chemoimmunotherapy for patients with NSCLC with programmed cell death 1 ligand 1 (PD-L1) levels less than 1%. Objective To compare neoadjuvant chemoimmunotherapy with chemotherapy by adverse events and surgical, pathological, and efficacy outcomes using recently published randomized clinical trials and nonrandomized trials. Data Sources MEDLINE and Embase were systematically searched from January 1, 2013, to October 25, 2023, for all clinical trials of neoadjuvant chemoimmunotherapy and chemotherapy that included at least 10 patients. Study Selection Observational studies and trials reporting the use of neoadjuvant radiotherapy, including chemoradiotherapy, molecular targeted therapy, or immunotherapy monotherapy, were excluded. Main Outcomes and Measures Surgical, pathological, and efficacy end points and adverse events were pooled using a random-effects meta-analysis. Results Among 43 eligible trials comprising 5431 patients (4020 males [74.0%]; median age range, 55-70 years), there were 8 randomized clinical trials with 3387 patients. For randomized clinical trials, pooled overall survival (hazard ratio, 0.65; 95% CI, 0.54-0.79; I 2 = 0%), event-free survival (hazard ratio, 0.59; 95% CI, 0.52-0.67; I 2 = 14.9%), major pathological response (risk ratio, 3.42; 95% CI, 2.83-4.15; I 2 = 31.2%), and complete pathological response (risk ratio, 5.52; 95% CI, 4.25-7.15; I 2 = 27.4%) favored neoadjuvant chemoimmunotherapy over neoadjuvant chemotherapy. For patients with baseline tumor PD-L1 levels less than 1%, there was a significant benefit in event-free survival for neoadjuvant chemoimmunotherapy compared with chemotherapy (hazard ratio, 0.74; 95% CI, 0.62-0.89; I 2 = 0%). Conclusion and Relevance This study found that neoadjuvant chemoimmunotherapy was superior to neoadjuvant chemotherapy across surgical, pathological, and efficacy outcomes. These findings suggest that patients with resectable NSCLC with tumor PD-L1 levels less than 1% may have an event-free survival benefit with neoadjuvant chemoimmunotherapy.
oncology
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve This paper aims to evaluate the clinical efficacy of neoadjuvant chemoimmunotherapy compared to traditional neoadjuvant chemotherapy in patients with non-small cell lung cancer (NSCLC). Specifically, the paper conducts a systematic review and meta-analysis to compare these two treatment methods in terms of surgical, pathological, and efficacy outcomes, as well as adverse events. Additionally, the paper focuses on patients with tumor programmed death-ligand 1 (PD-L1) expression levels below 1%, exploring the efficacy of neoadjuvant chemoimmunotherapy in this subgroup. ### Main Research Background 1. **Importance of the Study**: - Currently, there is no comprehensive meta-analysis evaluating the impact of neoadjuvant chemoimmunotherapy on clinical outcomes in NSCLC patients in both randomized and non-randomized trials. - The efficacy of neoadjuvant chemoimmunotherapy in NSCLC patients with PD-L1 expression levels below 1% is controversial. 2. **Objectives of the Study**: - To compare the differences between neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy in terms of adverse events, surgical, pathological, and efficacy outcomes. - To specifically focus on patients with PD-L1 expression levels below 1%, evaluating their event-free survival (EFS) and overall survival (OS) under neoadjuvant chemoimmunotherapy. 3. **Data Sources**: - A systematic search of the MEDLINE and Embase databases from January 2013 to October 25, 2023, including clinical trials with at least 10 patients. 4. **Study Selection**: - Excluded observational studies and trials reporting the use of neoadjuvant radiotherapy, including chemoradiotherapy, molecular targeted therapy, or immunotherapy monotherapy. 5. **Main Outcomes and Measures**: - Summarized surgical, pathological, and efficacy outcomes as well as adverse events using random-effects meta-analysis. ### Main Results 1. **Overall Results**: - Among 43 eligible trials, a total of 5431 patients were included (74.0% male, median age range 55-70 years), with 8 randomized clinical trials comprising 3387 patients. - For randomized clinical trials, neoadjuvant chemoimmunotherapy showed superior overall survival (HR, 0.65; 95% CI, 0.54-0.79; I²= 0%), event-free survival (HR, 0.59; 95% CI, 0.52-0.67; I²= 14.9%), major pathological response (RR, 3.42; 95% CI, 2.83-4.15; I²= 31.2%), and complete pathological response (RR, 5.52; 95% CI, 4.25-7.15; I²= 27.4%) compared to neoadjuvant chemotherapy. 2. **Patients with PD-L1 Expression Levels Below 1%**: - For patients with baseline tumor PD-L1 expression levels below 1%, neoadjuvant chemoimmunotherapy was significantly superior to neoadjuvant chemotherapy in terms of event-free survival (HR, 0.74; 95% CI, 0.62-0.89; I²= 0%). ### Conclusion and Significance This study found that neoadjuvant chemoimmunotherapy is superior to neoadjuvant chemotherapy in terms of surgical, pathological, and efficacy outcomes. Particularly for resectable NSCLC patients with tumor PD-L1 expression levels below 1%, neoadjuvant chemoimmunotherapy has a significant advantage in event-free survival. These findings provide important evidence for the future approval of neoadjuvant drugs.